URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Michael Meyers Biography and Net Worth

SVP of Syndax Pharmaceuticals

Michael L. Meyers, M.D., Ph.D. has served as our Senior Vice President, Chief Medical Officer since May 2016. Dr. Meyers previously served as our Senior Vice President, Chief Development Officer from August 2015 to April 2016. Prior to joining us, Dr. Meyers held a number of senior roles at Johnson & Johnson, a publicly traded pharmaceutical, medical device, and consumer packaged goods company, serving as Vice President, GU Oncology, Compound and Clinical Leader, and as Vice President, Oncology Scientific Innovation in Johnson and Johnson’s London Innovation Centre. Dr. Meyers also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc., a privately held life sciences company, predecessor to Sanofi-Aventis U.S. LLC, and worked in oncology clinical development at the Schering-Plough Research Institute. Dr. Meyers served on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma. He received his M.D. and his Ph.D. in Microbiology and Immunology from Albert Einstein College of Medicine in New York and was elected to the Alpha Omega Alpha, the national medical school honor society. Dr. Meyers completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship, where he served as Chief Fellow in Medical Oncology, at Memorial Sloan Kettering Cancer Center.

What is Michael L. Meyers' net worth?: The estimated net worth of Michael L. Meyers is at least $204,911.28 as of April 26th, 2021. Dr. Meyers owns 15,666 shares of Syndax Pharmaceuticals stock worth more than $204,911 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Meyers may own. Learn More about Michael L. Meyers' net worth.
How do I contact Michael L. Meyers?: The corporate mailing address for Dr. Meyers and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Michael L. Meyers' contact information.
Has Michael L. Meyers been buying or selling shares of Syndax Pharmaceuticals?: Michael L. Meyers has not been actively trading shares of Syndax Pharmaceuticals within the last three months. Most recently, on Monday, April 26th, Michael L. Meyers bought 500 shares of Syndax Pharmaceuticals stock. The stock was acquired at an average cost of $15.46 per share, with a total value of $7,730.00. Following the completion of the transaction, the senior vice president now directly owns 15,666 shares of the company's stock, valued at $242,196.36. Learn More on Michael L. Meyers' trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Pierre Legault (Director), Michael Metzger (COO), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. The most recent insider tranaction occured on June, 14th when CFO Keith A Goldan bought 1,250 shares worth more than $25,037.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 6/14/2024.

Michael L. Meyers Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/26/2021	Buy	500	$15.46	$7,730.00	15,666
3/21/2019	Buy	1,104	$4.92	$5,431.68

Michael L. Meyers Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $13.08

$12.75

$13.15

50 Day Range

MA: $17.30

$12.85

$21.81

2 Week Range

Now: $13.08

$12.75

$25.34

Volume

4,993,342 shs

Average Volume

1,251,799 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.